



# Recombinant Human IGF-BP6

20150227BB



**FOR RESEARCH ONLY! NOT FOR HUMAN USE!**

<b>Cat.-no.:</b>	<b>100-377</b>
<b>Size:</b>	20 µg
<b>Lot. No.:</b>	According to product label

## Scientific Background

<b>Gene-ID (NCBI):</b>	3489
<b>Synonyms:</b>	Igfbp6; IBP6

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.

## Sequence

```
RCPGCGQGVQ AGCPGGCVVE EDGGSPAEGC AEAEGCLRRE  
GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA  
RAPAVAEENP KESKPPQAGTA RPQDVNRRDQ QRNPGTSTTP  
SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV  
PNCDRHRGFYR KRQCRSSQGG RRGPCWCVDR MGKSLPGSPD  
GNGSSSCPTG SSG
```

## Database References

<b>Protein RefSeq:</b>	NP_002169.1
<b>Uniprot ID:</b>	P24592
<b>mRNA RefSeq:</b>	NM_002178

## Product Specifications

<b>Expressed in</b>	Insect cells
<b>Purity</b>	> 95% by SDS-PAGE & HPLC analyses
<b>Endotoxin level</b>	< 0.1 ng /µg of protein (<1EU/µg).
<b>Formulation</b>	lyophilized
<b>Length (aa):</b>	213
<b>MW:</b>	22.6 kDa

**Biological Activity:** Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED50 for this effect is 0.1 – 0.4 µg/ml.



**AVOID REPEATED FREEZE AND THAW CYCLES!**